Management of hormone-refractory disease

BJU International, Supplement

Volumn 94, Issue 3, 2004, Pages 16-17

  Hennequin, C ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; BRYOSTATIN; CALCITRIOL; CORTICOSTEROID; DIETHYLSTILBESTROL; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; FLUTAMIDE; GEFITINIB; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; NAVELBINE; NILUTAMIDE; OBLIMERSEN; PACLITAXEL; PLACEBO; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89; TAXANE DERIVATIVE; VINBLASTINE; ZOLEDRONIC ACID;

ADVANCED CANCER; BEAM THERAPY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; GENE AMPLIFICATION; HORMONE RESISTANCE; HUMAN; ORCHIECTOMY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR SENSITIVITY; REFRACTORY PERIOD; SPINAL CORD COMPRESSION; SPINAL CORD DECOMPRESSION; TESTOSTERONE BLOOD LEVEL; VERTEBRA FRACTURE;

ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 11144248213     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154: 448-53
2. Scher HI, Liebertz C, Kelly WK et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15: 2928-38
3. Joyce R, Fenton MA, Rode P et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159: 149-53
4. Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology 2001; 58: 1016-20
5. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991-8
6. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone. Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590-7
7. Tannock IF, Osoba D, Stockier MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64
8. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123-8
9. Gravis G, Bladou F, Salem N et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 2003; 98: 1627-34
10. Oudard S, Legrier ME, Boye K et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169: 1729-34
11. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457-65
12. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68